$90m IPO Sets Up Sweden's Calliditas For Phase III Readout
Biotech Sector Listings Defying Pandemic
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
You may also be interested in...
The Swedish biotech’s oral corticosteroid for a kidney disorder has left the EMA’s CHMP with questions on its manufacturing, delaying an EU approval opinion that had been slated for the first quarter.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.